Prostate Neoplasms Clinical Trial
Official title:
A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of ASG-5ME Monotherapy in Subjects With Castration-Resistant Prostate Cancer (CRPC)
Verified date | June 2013 |
Source | Astellas Pharma Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this dose escalation study is to determine the Maximum Tolerated Dose (MTD) and the recommended Phase 2 dose of ASG-5ME in subjects with castration-resistant prostate cancer (CRPC).
Status | Completed |
Enrollment | 46 |
Est. completion date | February 2013 |
Est. primary completion date | February 2013 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subject has histologically-confirmed castration-resistant prostate cancer and meets at least 1 of the following criteria: - subject's disease has progressed on or after available standard therapy -OR- - there is no effective standard therapy available for treating the subject's disease -OR- - subject or his disease is not suitable for standard therapy -OR- - subject chooses to defer or decline standard therapy (subject is adequately informed of the availability of clinically meaningful therapy and chooses instead to partake in this research using a product with no documented clinical activity) - Testosterone = 50 ng/dL - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Life expectancy of > 6 months as evaluated and documented by the investigator - Hematologic function, as follows (no red blood cell (RBC) or platelet transfusions are allowed within 4 weeks of the first dose of ASG-5ME): - Absolute neutrophil count (ANC) = 1.5 x 109/L - Platelet count = 100 x 109/L - Hemoglobin = 9 g/dL - Renal function, as follows: creatinine = 1.5 x upper limit of normal (ULN), or creatinine clearance of > 60 mL/min if serum creatinine is > 2.0 mg/dL - Total bilirubin < 1. 5 x ULN - Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)= 1.5 x ULN - International Normalized Ratio (INR) < 1.3 (or < 3.0 if on therapeutic anticoagulation) - Serum calcium = ULN - Subjects must be taking and agree to remain on a stable dose of luteinizing hormone-releasing hormone (LHRH) agonist therapy or gonadotropin-releasing hormone (GnRH) antagonist for the duration of the trial if not surgically castrated - Additional Inclusion criteria for Chemotherapy Naïve Cohort: No prior systemic cytotoxic chemotherapies - Additional Inclusion criteria for Chemotherapy Exposed Cohort: - Documented disease progression during or after docetaxel treatment or intolerability to docetaxel treatment - No additional prior chemotherapy for CRPC is allowed Exclusion Criteria: - History of central nervous system metastasis, including incompletely treated epidural disease - History of other primary malignancy (including premalignant myeloid malignancy e.g. myelodysplastic syndrome), unless: - Curatively resected non-melanomatous skin cancer - Other malignancy curatively treated with no known active disease present and no treatment administered for the last 3 years - Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 12 months of study enrollment, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by outsubject medication - The following treatments are not allowed within 4 weeks of enrollment: cytotoxic chemotherapy, radiation therapy or the dietary supplement PC-SPES - Use of prednisone (or equivalent corticosteroids) > 20 mg/day are not allowed. Doses < 20 mg/day are allowed only if they have been at the same dose for > 4 weeks - Use of anti-androgen therapy (ie, flutamide, bicalutamide and nilutamide) within 6 weeks of study enrollment; non-responders to second-line anti-androgen therapy do not require the 6 week withdrawal period - Monoclonal antibody therapy within 3 months of enrollment with the exception of denosumab (prior or concurrent use of denosumab is allowed) - Peripheral neuropathy of = grade 2 as defined by the CTCAE criteria version 4.0 - Major surgery (that requires general anesthesia) within 4 weeks of study enrollment - Active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) within 72 hours of screening - Use of any investigational drug (including marketed drugs not approved for this indication) within 30 days prior to enrollment - History of thromboembolic events and bleeding disorders = 3 months (e.g., deep vein thrombosis (DVT) or pulmonary embolism (PE)) - Known positive test for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B surface antigen |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | The Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland |
United States | The Karmanos Cancer Institute | Detriot | Michigan |
United States | University of Wisconsin Madison, Carbone Cancer Center | Madison | Wisconsin |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Astellas Pharma Inc | Seattle Genetics, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety assessed by recording of adverse events, laboratory assessments and vital signs | For 12 weeks during treatment period and up to 4 weeks follow up | No | |
Primary | Pharmacokinetics assessment of ASG-5ME blood levels through analysis of blood samples | Up to day 15 for cycle 1 and cycle 4 and pre-dose for cycles 2 and 3; every 3 weeks during the second 12 weeks of treatment; and if subject continues on study drug, every 12 weeks thereafter | No | |
Secondary | Incidence of anti-ASG-5ME antibody formation | Baseline; up to day 64 during the first 12 weeks; and if subject continues on study drug, every 3 weeks during the second 12 weeks of treatment and every 12 weeks thereafter | No | |
Secondary | Incidence of tumor response (complete or partial response) | Baseline and every 12 weeks while on study drug | No | |
Secondary | Changes in prostate-specific antigen (PSA) levels | Baseline; up to day 64 during the first 12 weeks; and if the subject continues on study drug, every 3 weeks thereafter | No | |
Secondary | Changes in bone scans | Baseline and every 12 weeks while on study drug | No | |
Secondary | Changes in circulating tumor cells | Baseline; up to day 64 during the first 12 weeks; and if the subject continues on study drug, every 3 weeks during the second 12 weeks of treatment and every 12 weeks thereafter | No | |
Secondary | Changes in cytokeratin-18 levels | Up to day 79 and 4 weeks after the last dose of study drug | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00970203 -
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
|
Phase 2 | |
Completed |
NCT01400555 -
A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
Phase 1 | |
Terminated |
NCT03685591 -
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00643617 -
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
|
N/A | |
Recruiting |
NCT01581749 -
Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
|
Phase 4 | |
Completed |
NCT01424930 -
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT00544440 -
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
|
Phase 2 | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Suspended |
NCT02759744 -
Fusion Guided Focal Laser Ablation of Prostate Cancer
|
N/A | |
Completed |
NCT00474383 -
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
|
Phase 2 | |
Completed |
NCT01284920 -
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02319239 -
Prostate Cancer Stereotactic Radiotherapy
|
N/A | |
Completed |
NCT00910754 -
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
Completed |
NCT00972309 -
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
|
Phase 1 | |
Terminated |
NCT03531827 -
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
|
Phase 2 | |
Completed |
NCT00167648 -
Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05577689 -
Novel Therapy Target in Metastatic Prostate Cancer
|
||
Enrolling by invitation |
NCT03173924 -
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
|
Phase 2 | |
Completed |
NCT04703543 -
Evaluating the Role of Both PSMA and 64Cu-PET/CT Total Body in Patients With Locally Relapsed Prostate Cancer
|
N/A | |
Completed |
NCT01477749 -
Sipuleucel-T Manufacturing Demonstration Study
|
Phase 2 |